Medical device strategy · Clinical evidence · Market access
The most expensive decisions in a device’s life are often made before the first patient..
Independent advice for medical device founders, boards and investors on clinical evidence, market access and commercial strategy, from first-in-human to exit.
Approval is one milestone; getting paid for, adopted and acquired are the others.
Planning a first-in-human or pivotal study? That’s the best time to talk.
FOUR EARLY DECISIONS
Clinical, access and commercial, planned together.
Clinical & device
The trial
Endpoints regulators, payers and clinicians accept
The device
Design choices that set the code and payment
Market & exit
The market
Where to launch, who pays, what centres can afford
The exit
What investors and acquirers need to see
Approved, paid for and adopted
The trial
Endpoints regulators, payers and clinicians accept
The device
Design choices that set the code and payment
The market
Where to launch, who pays, what centres can afford
The exit
What investors and acquirers need to see
Each is easiest to change before the first patient is treated. After approval, most are slow and expensive to revisit.
Clinical evidence
Trial design input on endpoints, comparators and sites, so one study answers regulators, payers and clinicians.
Market access
Commercial strategy
Previous clients






Epiminder
Nocionix
01
The problem
Approval is only half the journey.
New device procedures rarely fit existing codes or tariffs. Surgeons and centres won’t adopt a therapy that loses them money, and acquirers want to see both before they buy. Small design decisions matter more than most founders expect: something as simple as how a lead connects to the implant can change which code applies and roughly halve what the procedure pays. Found after approval, that’s slow and expensive to fix.
THE GAP BETWEEN APPROVAL AND ADOPTION
US
median time from FDA authorisation to any Medicare coverage for novel devices and diagnostics.¹
US
of 64 novel technologies reached a Medicare coverage milestone during the study’s follow-up.¹
UK
estimated average time for a new device to go from successful clinical trial to mainstream NHS adoption.²
¹ Sexton ZA et al. JAMA Health Forum. 2023;4(8):e232260. Technologies authorised 2016–2019. ² NHS Improvement estimate, cited in the House of Commons, Westminster Hall debate on Innovation in the NHS, 3 March 2020.
After approval: the hurdles, by market
Each country values different things, and it all takes longer than you’d think.
Coding
AMA CPT
A new procedure needs the right code, and the evidence bar for each code category is different.
Coverage
CMS & payers
Coverage decisions turn on whether your trial answers the questions payers actually ask.
Payment
Facility economics
Physician and surgery-centre economics drive adoption. If they don’t make a reasonable margin, they won’t use it, however good the data.
02
Where to start
The two-minute readiness check
0 of 5 answered
Five questions every medical device board should be able to answer before the pivotal protocol is locked.
1. Does your pivotal protocol collect health-economic and resource-use data?
2. Do you know which procedure code you will use in each target market?
3. Have you modelled hospital payment against your device and procedure cost?
4. Have payers, not just regulators, accepted endpoints like yours before?
5. Has your board seen a timeline from approval to first reimbursed sale?
Start with a Readiness Review.
Most of what I find in these reviews is cheap to fix before the protocol is locked. A year later, much of it can’t be fixed at all.
Where most clients start
I look at your protocol, device design, evidence plan, target markets and investor story, and tell you where things are likely to get stuck, whether with regulators, payers, clinicians or buyers, and what to change. You get a written report your board can act on.
Timing
Planned around your protocol deadline
Fee
Fixed, agreed up front
Markets
UK · EU · US
You leave with
Evidence-gap analysis of your pivotal protocol against what payers and clinicians will ask
Coding route for the UK and US, with the risks in each
Access plan and timeline from approval to first reimbursed sale
Strategic-fit view: what an investor or acquirer would want to see
Board and investor summary you can share as it is
See an example scorecard from a review
Need more than a review? Some clients keep me on afterwards for ongoing access support, scoped and agreed with you.
Limited availability. I take a small number of engagements alongside my current role, and never with directly competing technologies.
Specialist input. If a project needs health economics or regulatory expertise, I’ll tell you and can introduce people I trust.
03
For investors and acquirers
What I’d want to know before investing.
A therapy can have strong clinical data and still struggle to be paid for, adopted or bought. The gap most often missed is the economics of whoever pays: if the clinician, hospital or clinic can’t make a reasonable margin from using it, or patients won’t pay for it themselves, it won’t be adopted, however good the data. I offer a practical, independent view of a therapy’s evidence, payment and adoption path, alongside your formal diligence.
Questions I can help you answer
Will the evidence hold up?
Whether the trial design and endpoints will satisfy payers and clinicians, not just regulators.
How long until it is actually paid for?
Coding, coverage and payment in the markets that matter, and whether the plan’s timing is realistic.
Will doctors and centres adopt it?
Who uses it, how it fits their day, and whether the economics work for the clinician and the site of care..
How it works: most investors start with a one-hour call about a specific company. If that’s useful, we can agree a short written view or help on particular questions.
Confidential and conflict-checked. I’m happy to sign an NDA before we talk, and I don’t advise on companies with competing technologies or connected to my current employer.
04
Experience
Situations you might recognise.
Every company is different, but most of these will sound familiar.
Breakthrough-designated implant · US
COMMERCIAL STRATEGY
Deciding where to launch
Non-Invasive Nerve Stimulation · EU.
COMMERCIAL STRATEGY
Launching with no reimbursement route
Building markets country by country, setting up distribution, and working with clinicians, payers and patient groups.
Implantable headache therapy ·Nordics, Spain, Ialty
COMMERCIAL STRATEGY
Preparing for investors or a buyer
Early-stage neuromodulation · US and EU.

05
What clients say
“
Founder, PD Neurotechnology
“Mercian Medical investigated the EU market in a way that helped shape our decision to pursue CE approval. We now have a clear understanding of what needs to be achieved and when.”
Former CEO, Spark Biomedical
“The key to access and reimbursement is knowing not only the processes but also the stakeholders. Mercian Medical's network has been key to us starting to build a presence and awareness that will prove invaluable as we further expand our therapy..”
Former COO, Nalu Medical
Latest thinking · November 2026
A short guide for medical device founders and boards, to share before your protocol is locked.

06
About
Started in the NHS. Grew neuromodulation businesses. Led a start-up to acquisition.
I started as a cardiac technician in the NHS, moved into device sales and clinical research, and spent two decades building medical device businesses, from UK P&L leadership at St. Jude Medical to opening new European markets for an emerging therapy. Most of my career has been in cardiology and neuromodulation, but the same principles apply across novel implantable medical devices.
I set up Mercian Medical in 2018 to advise companies without a UK presence. Since then I’ve led a headache device start-up through to its acquisition, and now lead commercialisation at MAN & SCIENCE, covering US market access, trial strategy and investor discussions. The work has since moved towards what I enjoy most: early-stage companies around first-in-human, when a simple decision can change where they are three to five years later. At events like LSX Europe I’m still struck by how little many founders have been told about reimbursement, coding and adoption. That’s the gap I try to fill.
Education & credentials
BMedSci (Hons), University of Birmingham
PgCert Neuromodulation & Pain Management, Queen Mary (2024)
EEPIN, City University London
Professional Diploma in Marketing, CIM
ICH GCP E6(R3) · ISO 14155:2020
Career
1995
Cardiac Technician
City Hospital NHS Trust
2000
Sales & Clinical Research
Biotronik UK and Medtronic
2008
BU Manager, Neuromodulation
St. Jude Medical UK
2014
Senior Regional Sales Director
Autonomic Technologies
2018
Founded Mercian Medical
Independent consultancy
2021
CEO, Palion Medical
Acquired by MAN & SCIENCE
Now
Global Head, Marketing & Commercialisation
MAN & SCIENCE
07
Questions
What founders and investors ask first.
Do you only work on reimbursement?
Do you only work with implants or neuromodulation?
We’re pre-first-in-human. Is it too early?
We’re already approved. Is it too late?
What does a Readiness Review cost?
What do you need from us to get started?
How quickly can you start?
Can you help on a live deal?
How do you handle confidentiality and conflicts?
Can you help with health economics or regulatory submissions?
How do you fit this around your current role?
Where are you based, and do you travel?
Whether you’re planning a first study, approved but not yet paid for, or looking at an investment, tell me where you are and what you’re working on. If I can help, I’ll say how. If I can’t, I’ll try to point you to someone who can.
Or email enquiry@mercianmedical.com

